Background Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid
cells that are implicated in the pathogenesis of multiple sclerosis. Evobrutinib is a selective …

Background Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine
kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which …

Abstract Purpose of Review Multiple sclerosis (MS) is an inflammatory disease of the central
nervous system (CNS) with a chronic and often progressive disease course. The current …

Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system
(CNS) leading to demyelination and neurodegeneration. Although its etiology is not fully …

In multiple sclerosis (MS) persisting disability can derive from acute relapses or,
alternatively, from slow and steady deterioration, termed chronic progression. Emerging data …

Introduction B cells have increasingly come under the spotlight as mediators of inflammatory
central nervous system (CNS) demyelinating diseases such as multiple sclerosis (MS). B …

Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated
worsening of disability, which is assumed to be mainly associated with transient infiltration of …

Background The monoclonal antibody ublituximab enhances antibody-dependent cellular
cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of …

Increasing evidence suggests that B cells contribute both to the regulation of normal
autoimmunity and to the pathogenesis of immune mediated diseases, including multiple …

Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the
treatment of B cell malignancies. However, further refinement is needed to this class of …